Fecal Occult Blood Test in Patients on Low-Dose Aspirin, Warfarin, Clopidogrel, or Non-steroidal Anti-inflammatory Drugs
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
To determine the effect of anticoagulants and antiplatelet medications on the positive-predictive-value of fecal occult blood test (FOBT).
All patients who underwent a colonoscopy at our institution from 1995 to 2006 for a positive FOBT were identified. Medical records were searched, and patients were stratified into five groups selected a priori: low-dose aspirin, NSAIDs, warfarin, clopidogrel, or controls. The positive-predictive-value of FOBT for advanced colonic neoplasia was computed for each group.
During the study period, 1,126 patients underwent colonoscopy for a positive FOBT and met entry criteria. The average age of study participants was 69 years and most were men. The positive-predictive-value of FOBT for advanced colon neoplasia was significantly higher in the control group (30.5%) when compared to those on low-dose aspirin (20.5%; p = 0.003), NSAIDs (19.7%; p = 0.003), clopidogrel (7.3%; p = 0.002), or warfarin (20%; p = 0.05). The positive-predictive-value of FOBT was significantly lower for those on clopidogrel than those on low-dose aspirin (p = 0.04) and NSAIDs (p = 0.05), but not warfarin (p = 0.08). The positive-predictive-value for FOBT was similar for those on aspirin, NSAIDs, and warfarin. There was a linear trend between the number of number of positive FOBT cards and prevalence of advanced colon neoplasia (p = 0.01).
Anticoagulants and antiplatelet medications lower the positive-predictive-value of FOBT for advance colonic neoplasia and should be stopped if clinically feasible prior to stool collection.
- Bond JH. The place of fecal occult blood test in colorectal cancer screening in 2006: the US perspective. Am J Gastroenterol. 2006;101:219–221. CrossRef
- CDC. Increasing use of colorectal cancer tests. Morb Mortal Wkly Rep. 2006;55:308–311.
- El-Serag H, Petersen L, Hampel H, Richardson P, Cooper G. The use of screening colonoscopy for patients cared for by the Department of Veterans Affairs. Arch Intern Med. 2006;166:2202–2208. CrossRef
- Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology. 2003;124:544–560. CrossRef
- Ransohoff D, Lang C. Screening for colorectal cancer with the fecal occult blood test: a background paper. Am Coll Physicians. 1997;126:811–822.
- Lieberman DA, Weiss DG. 380 FtVACSG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med. 2001;345:555–560. CrossRef
- Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med. 1993;328:1365–1371. CrossRef
- Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467–1471. CrossRef
- Hardcastle JD, Chamberlain JO, Robinson MHE, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;148:1472–1477. CrossRef
- Bond J. Fecal occult blood test screening for colorectal cancer. Gastrointest Endosc Clin N Am. 2002;12:11–21. CrossRef
- Helm J, Russo M, Biddle A, Simpson K, Ransohoff D, Sandler R. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing. Am J Gastroenterol. 2000;95:3250–3258. CrossRef
- Greenberg P, Cello J, Rockey D. Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease. Am J Med. 1996;100:598–604. CrossRef
- Fleming J, Ahlquist D, McGill D, Zinsmeister A, Ellefson R, Schwartz S. Influence of aspirin and ethanol on fecal blood levels as determined by using the HemoQuant assay. Mayo Clin Proc. 1987;62:159–163.
- Norfleet R. 1, 300 mg of aspirin daily does not cause positive fecal hemoccult tests. J Clin Gastroenterol. 1983;5:123–125. CrossRef
- Kahi C, Imperiale T. Do aspirin and nonsteroidal anti-inflammatory drugs cause false-positive fecal occult blood test results? A prospective study in a cohort of veterans. Am J Med. 2004;117:837–841. CrossRef
- Kewenter J, Svanvik J, Svensson C, Wallgren K. The diagnostic value of the hemoccult as a screening test in patients taking anticoagulants. Cancer. 1984;54:3054–3058. CrossRef
- Bini E, Rajapaksa R, Weinshel E. Positive predictive value of fecal occult blood testing in persons taking warfarin. Am J Gastroenterol. 2005;100:1586–1592. CrossRef
- Cryer B. Reducing the risks of gastrointestinal bleeding with antiplatelet therapies. N Engl J Med. 2005;352:287–289. CrossRef
- van Hecken A, Depre M, Wynants K, et al. Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers. Drug Metabol Drug Interact. 1998;14:193–205.
- Ecclissato C, Carvalho AF, Ferraz JG, de Nucci G, De Souza CA, Pedrazzoli J Jr. Prevalence of peptic lesions in asymptomatic, healthy volunteers. Dig Liver Dis. 2001;33(5):403–406. CrossRef
- Fecal Occult Blood Test in Patients on Low-Dose Aspirin, Warfarin, Clopidogrel, or Non-steroidal Anti-inflammatory Drugs
Digestive Diseases and Sciences
Volume 55, Issue 6 , pp 1637-1642
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Colon cancer
- Occult blood
- Fecal occult blood test
- Industry Sectors
- Author Affiliations
- 1. Division of Gastroenterology, Minneapolis Veterans Affairs Medical Center, Minneapolis, MN, USA
- 2. Department of Medicine, University of Minnesota, Minneapolis, MN, USA
- 3. Division of Gastroenterology, Beth Israel Deaconess Medical Center [RABB-ROSE 101], 330 Brookline Avenue, Boston, MA, 02215, USA